Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297032 · ClinicalTrials.gov registry record · NA
Effects of Quercetin on Metabolic Health
A NA study, sponsored by Thorne HealthTech.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT05297032: Clinical Trial NA study, sponsored by Thorne HealthTech.
NCT05297032 is a NA study that was terminated before completion, run by Thorne HealthTech. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05297032, a NA study, was terminated before completion, sponsored by Thorne HealthTech.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
Quercetin is a natural flavonoid compound widely found in vegetables, fruits, and nuts. It has a long history of use as a dietary supplement. This study aims to assess results from a computational model suggesting that quercetin may offer novel benefits to metabolic health. Participants will take quercetin (as Quercetin Phytosome, a proprietary formulation with enhanced absorption properties) for 90 days while keeping lifestyle habits consistent throughout to estimate net effects of quercetin as much as possible. Blood samples will be collected at the beginning and end of the study to assess the effects of quercetin supplementation on metabolic health metrics such as LDL cholesterol, blood sugar, liver, kidney and immune function and calculated metabolic age. In addition, questionnaires will be completed to ensure compliance with study requirements and assess potential quercetin benefits in the participants' quality of life. This work will provide a proof-of-concept from a computational model of nutraceutical compounds and proposes a new application of quercetin in support of healthy human metabolism.
Primary Outcome
Quantitative changes before and after intervention in calculated metrics of biological age. These metrics are calculated by applying the Klemera-Doubal algorithm to a proprietary set of clinical measures. (Scale for each metric: 0-120) (ref: https://academic.oup.com/biomedgerontology/article/74/Supplement\_1/S52/5625183?login=true)
Interventions
- DIETARY_SUPPLEMENT Quercetin Phytosome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2022-09-02 |
| Phase | NA |
Why NCT05297032 stopped before completion
NCT05297032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Quercetin Phytosome is the first listed.
NCT05297032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05297032 about?
NCT05297032 is a clinical study titled "Effects of Quercetin on Metabolic Health". Quercetin is a natural flavonoid compound widely found in vegetables, fruits, and nuts. It has a long history of use as a dietary supplement. This study aims to assess results from a computational model suggesting that quercetin may offer novel benefits to metabolic health. Participants will take qu...
What is the current status of trial NCT05297032?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2022-03-24. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT05297032?
The interventions under investigation include: Quercetin Phytosome (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05297032?
This trial is sponsored by Thorne HealthTech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05297032's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI